group II sPLA₂ Antibodies

Santa Cruz Biotechnology delivers a wide array of group II sPLA₂ monoclonal antibodies for research in lipid metabolism and inflammatory processes. Group II sPLA₂ monoclonal antibodies perform effectively across multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Group II secreted phospholipases A₂ (sPLA₂) catalyze the hydrolysis of phospholipids, releasing fatty acids and lysolipids, which act as key mediators in inflammation and cell signaling. Group II sPLA₂ influences numerous physiological and pathological processes, including immune responses, neurodegenerative diseases, and cancer progression. Research focused on group II sPLA₂ continues to reveal new insights about inflammatory diseases and related conditions. Advanced detection methods using specific molecular markers help researchers track group II sPLA₂ activity in various biological systems. Investigating group II sPLA₂ expression patterns provides valuable information about disease mechanisms and potential therapeutic targets. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of group II sPLA₂ and its impact on human health.